Abstract
To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies
for metastatic colorectal cancer (mCRC), we performed a systematic review of published
cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria
and revealed varying levels of value among current treatment strategies. Older agents
such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments.
More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab,
and panitumumab, do not appear to be cost-effective treatments at their current costs.
The analytical methods used within the papers varied widely, and this variation likely
plays a significant role in the heterogeneity in incremental cost-effectiveness ratios.
The cost-effectiveness of current treatment strategies for mCRC is highly variable.
Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective,
and this is primarily driven by high drug costs.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Colorectal cancer statistics, 2014.CA Cancer J Clin. 2014; 64: 104-117
- Projections of the cost of cancer care in the United States: 2010-2020.J Natl Cancer Inst. 2011; 103: 117-128
- Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.J Clin Oncol. 2008; 26: 2013-2019
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.Lancet Oncol. 2013; 14: 749-759
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 303-312
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.J Clin Oncol. 2004; 22: 1382-1388
- Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.J Clin Oncol. 2008; 26: 2099-2105
- Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases.Ann Surg. 2008; 248: 994-1005
- Radiofrequency ablation of hepatic malignancies: inexpensive and minimally invasive but should it replace resection?.Ann Surg Oncol. 2003; 10: 1002-1004
- Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.Expert Rev Pharmacoecon Outcomes Res. 2005; 5: 153-162
- The value of new chemotherapeutic agents for metastatic colorectal cancer.Arch Intern Med. 2010; 170: 537-542
- A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.Am J Clin Oncol. 2009; 32: 49-55
- Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.Cancer. 2005; 104: 1871-1884
- Cost implications of new treatments for advanced colorectal cancer.Cancer. 2009; 115: 2081-2091
- First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States–based cost-effectiveness analysis.J Clin Oncol. 2015; 33: 1112-1118
- Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.Oncologist. 2014; 19: 892-899
- Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.J Natl Cancer Inst. 2012; 104: 1785-1795
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Int J Cancer. 2012; 131: 438-445
- Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.Clin Colorectal Cancer. 2014; 13: 219-225
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.Cancer. 2009; 115: 3858-3867
- Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases.J Surg Oncol. 2014; 109: 516-520
- Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis.J Surg Oncol. 2008; 97: 396-403
- Percutaneous cryoablation of metastatic lesions from colorectal cancer: efficacy and feasibility with survival and cost-effectiveness observations.ISRN Minim Invasive Surg. 2012; 2012
Goldstein DA, Ahmad BB, Chen Q, et al. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol. 2015, pii: JCO.2015.61.9569. [Epub ahead of print].
- Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.J Clin Oncol. 2006; 24: 3347-3353
- Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.J Clin Oncol. 2005; 23: 4866-4875
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Lancet Oncol. 2010; 11: 753-762
- Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.Clin Colorectal Cancer. 2012; 11: 263-267
- Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?.Ann Surg. 2004; 240: 1027-1034
- Economic studies in colorectal cancer: challenges in measuring and comparing costs.J Natl Cancer Inst Monogr. 2013; 2013: 62-78
- Health economic evaluations: the special case of end-stage renal disease treatment.Med Decis Making. 2002; 22: 417-430
- An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.Value Health. 2009; 12: 80-87
- The cost-effectiveness of total joint arthroplasty: a systematic review of published literature.Best Pract Res Clin Rheumatol. 2012; 26: 649-658
- Global cost-effectiveness of cataract surgery.Ophthalmology. 2007; 114: 1670-1678
- The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya.Am J Trop Med Hyg. 2003; 68: 161-167
- American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.J Clin Oncol. 2014; 32: 1277-1280
- Can money really be no object when cancer care is the subject?.J Clin Oncol. 2015; 33: 1093-1094
Article info
Publication history
Published online: October 14, 2015
Accepted:
October 5,
2015
Received in revised form:
October 1,
2015
Received:
June 26,
2015
Identification
Copyright
© 2016 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
